Kairos Pharma (KAPA) vs SciSparc (SPRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kairos Pharma is the larger company by market cap ($2.7 million vs $2.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KAPA | SPRC |
|---|---|---|
| Share price | $0.8103 | $4.47 |
| Market cap | $2.74M | $2.60M |
| 1-day change | -15.55% | +0.90% |
| P/E ratio (TTM) | — | 0.02 |
| EPS (TTM) | $-1.96 | $248.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.24 | $43.65 |
| 52-week low | $0.7827 | $2.98 |
| Distance from 52-week high | -91.23% | -89.76% |
| Analyst consensus | none | — |
| Avg. price target upside | +5947.14% | — |
| Average volume | 602.89K | 179.62K |
| Shares outstanding | 3.39M | 580.97K |
| Employees | 1 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kairos Pharma
KAPA stock →Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About SciSparc
SPRC stock →SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
KAPA vs SPRC FAQ
Which is bigger, Kairos Pharma or SciSparc?
Kairos Pharma (KAPA) is larger, with a market capitalization of $2.74M compared with $2.60M for SciSparc (SPRC).
Are Kairos Pharma and SciSparc in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.